NVIC Articles

Pneumococcal

Disease-Vaccine-Landing-Page/Pneumococcal

Latest articles

Browse Articles

Placeholder image
Page

Contraindications to receiving CAPVAXIVE (PCV21) vaccine documented in Merck’s package insert include a previous severe allergic reaction or anaphylaxis to any component of PCV21 or any vaccine containing diphtheria toxoid.Data...

Placeholder image
Page

According to the CAPVAXIVE (PCV21) package insert, in pre-licensing clinical trials, the most commonly reported side effects following vaccination included injection site pain, redness and swelling, muscle pain, headache, and...

Placeholder image
Page

CAPVAXIVE (PCV21), manufactured by Merck, was approved by the FDA through an accelerated approval process, in June 2024. According to the manufacturer, in adults 50 years and older, PCV21 targets...

Placeholder image
Page

CAPVAXIVE is a 21-valent pneumococcal conjugate vaccine (PCV) manufactured by Merck Sharp & Dohme Corp. containing S. pneumonia serotypes 3, 6A, 7F, 8, 9N, 10A, 11A, 12F, 15A, 15B (deOAc...

Placeholder image
Page

Contraindications to receiving the PNEUMOVAX23 (PPSV23) vaccine documented in Merck’s product insert include persons who have experienced a severe allergic reaction or anaphylaxis to any component of PNEUMOVAX23 (PPSV23).PNEUMOVAX23 (PPSV23)...

Placeholder image
Page

Contraindications to receiving VAXNEUVANCE (PCV15) vaccine documented in Merck’s package insert include persons who have experienced a severe allergic reaction or anaphylaxis to any component of PCV15 or any vaccine...

Placeholder image
Page

Contraindications to receiving the Prevnar 20 (PCV20) vaccine documented in Wyeth Pharmaceuticals package insert include persons who have experienced a severe allergic reaction or anaphylaxis to any component of PCV20...

Placeholder image
Page

Contraindications to receiving the Prevnar 13 (PCV13) vaccine documented in Wyeth Pharmaceuticals package insert include persons who have experienced a severe allergic reaction or anaphylaxis to any component of Prevnar...

Placeholder image
Page

As of December 27, 2024, there have been 28,316 serious adverse events reported to the Vaccine Adverse Events Reporting System (VAERS) in connection with pneumococcal vaccinations (PCV7, PCV13, PCV15, PCV20,...

Placeholder image
Page

According to the PCV20 package insert, in pre-licensing clinical trials, the most commonly reported side effects following vaccination in children 15 months of age and younger who received four doses...

Topics
Select disease / vaccine